

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF THE GROUP'S “MONTELUKAST SODIUM TABLETS AND CHEWABLE TABLETS”

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Montelukast Sodium Tablets (10mg)” and “Montelukast Sodium Chewable Tablets (4mg, 5mg)” (the “**Products**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China, being the second product of this type deemed as passing the consistency of quality and efficacy evaluation of generic drugs in China.

Montelukast sodium is an oral preparation that can notably improve symptoms of asthma and allergic rhinitis. It is used for the prevention and long-term treatment of asthma, including prevention of daytime and nighttime symptoms of asthma, treatment of asthma in aspirin-sensitive patients and prevention of exercise-induced bronchoconstriction; and also used for seasonal and perennial allergic rhinitis. Montelukast sodium tablets are used for patients 15 years of age and older whereas montelukast sodium chewable tablets are used for children 2 to 14 years of age.

The approval of the Products will further enrich the product portfolio of the Group and also provide a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 25 February 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

** For identification purpose only*